A team of Israeli researchers from Nes Ziona, Israel-based startup Accelerated Evolution Biotechnologies Ltd. (AEBi) have made a claim to have developed a concept that will pave the way to a cure for cancer. The researchers at AEBi have claimed their efforts have led to the invention of medicine that completely cures the cancer of any type and it will be available from 2020.

AEBi Cancer Cure Team

(L-R) CEO & Founder of  Accelerated Evolution Biotechnologies Ltd. (AEBI), Ilan Morad and Hanan Itzhaki, the chief science officer, at their lab
(Image Credit – Times of Israel)

AEBi develops the SoAP (simple object access protocol) platform which accesses functional leads over difficult targets. Further Dan Aridor claimed that “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market and our solution will be both generic and personal.”

The company first made the claim in the Jerusalem Post in last week, where the CEO of the company said, “We still have a long way to go, but in the end we believe we will have a cure for all kinds of cancer patients and with very few side effects.

Founded in the year 2000 by Ilan Morad, AEBi has developed a treatment, which it calls the MuTaTo (Multi-Target Toxin). MuTaTo is a family of molecules armed with peptides that have the ability to interact with a wide variety of proteins expressed by the cancer cells. Rather than just targeting one kind of protein, the molecules have the ability to target a number of proteins at the same time.

RELATED READING -  NITI Aayog in Partnership with Observer Research Foundation (ORF) Announced 2nd Edition of the Prestigious Agami Prize

The anti-cancer drug by AEBi is based on SoAP technology which involves the introduction of foreign DNA coding for a protein, such as an antibody, into a bacteriophage (a virus that infects bacteria). That foreign protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences, and small molecules.

The Jerusalem Post article reports the company has tested on mice and is on the cusp of clinical trials. Last month, AEBi received a US patent on their Drug Discovery technology platform.

According to reports by an International agency for research on cancer, every year 18.1 million new cancer cases diagnosed worldwide and every sixth death in the world is due to cancer making it the second most leading cause of death.

The “Not for Muslims” Clause

According to Aniqa Bajwa in Eastern Herald, “these innovations will become beneficial to people around the world except Iraq, Algeria, Bangladesh, Brunei, Iran, Kuwait, and Pakistan etc. due to their anti-semitic and anti-Israel mindset. Some Asian countries including India and Nepal can get benefit from these innovations and in the future can be a huge source of export of these medicines in other Asian counties.

References – Times of Israel,



Comments are closed.

You may also like